Clinical Trial Update: Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis [Phase 2, Phase 3]

View source ↗

Summary

Ongoing Phase 2/3 trial evaluating long-term safety of efgartigimod given IV and as a subcutaneous PH20 formulation in children with Generalized myasthenia grav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Efgartigimod (efgartigimod)

Snippet

Sponsor: argenx | Conditions: Generalized Myasthenia Gravis, gMG | Phase 2, Phase 3 | Status: ENROLLING_BY_INVITATION